tbuckley/cabot-search huggingface dataset:
Prospective, Multicenter Study of the Safety and Feasibility of Primary Stenting in Acute Myocardial Infarction: In-Hospital and 30-Day Results of the PAMI Stent Pilot Trial fn1fn1Funding for this study was provided in part by an unrestricted grant from Johnson &amp; Johnson Interventional Systems, Warren, New Jersey.
Authors: Gregg W. Stone, Bruce R. Brodie, John J. Griffin, Marie Claude Morice, Costantino Costantini, Frederick G. St. Goar, Paul A. Overlie, Jeffrey J. Popma, JoAnn McDonnell, Denise Jones, William W. O’Neill, Cindy L. Grines
Journal: Journal of the American College of Cardiology (1998)
Kronik yara tedavisi: İyileşmeyen yaraların bakımı ve yara örtüleri konusunda pratik bir rehber
Authors: Margaret A. Fonder, Gerald S. Lazarus, David A. Cowan, Barbara Aronson-Cook, Angela R. Kohli, veAdam J. Mamelak Baltimore, Maryland
Journal: Journal of the American Academy of Dermatology (2008)
THE MEETING-PLACE FOR INDUSTRIAL HEALTH
Authors: D O'HARA
Journal: Annals of Internal Medicine (1952)

Article1 February 1952THE MEETING-PLACE FOR INDUSTRIAL HEALTHDWIGHT O'HARA, F.A.C.P.DWIGHT O'HARA, F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-36-2-565 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptMany of you are familiar with a series of articles now being printed in the New England Journal of Medicine under the heading, "Fifty Years of Medical Progress." A subheading appears with each article which places its treatment in one of two categories: medicine as a science, or medicine as a social instrument. This differentiation provides a helpful approach for many of the subjects with which we concern ourselves. Within such a classification, industrial health may be considered as a social instrument as well as a science, and it is with this viewpoint that I undertake its present consideration.Social...Bibliography1. Green JO: The factory system, in its hygienic relations ("Annual Oration" of the Massachusetts Medical Society for 1846), Boston Medical Library, P. Vol. 322, pp. 24-25. Google Scholar2. Johnstone RT: Occupational medicine and industrial hygiene, 1948, C. V. Mosby Co., St. Louis, p. 389. International Labour Office, Geneva: Occupation and health 1: 542. Google Scholar3. O'Connor RB: An analysis of existing types of small-plant health in northeastern United States, Arch. Indust. Hyg. and Occup. Med. 3: 73 (Jan.) 1951. Google Scholar4. Strong GF: The industrial aspects of cardiac infarction, Ann. Int. Med. 33: 690 (Sept.) 1950. LinkGoogle Scholar5. Black SBBoth the thought and the phraseology of the last sentence are of industrial, not medical origin. See: Industry needs medicine and vice versa, Occup. Med. 5: 285 (March) 1948. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: DWIGHT O'HARA, F.A.C.P.*Presented at the Thirty-second Annual Session of the American College of Physicians, St. Louis, Mo., April 13, 1951. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 February 1952Volume 36, Issue 2_Part_2 Page: 565-570 Keywords Prevention, policy, and public health ePublished: 1 December 2008 Issue Published: 1 February 1952 PDF downloadLoading ...
The draft genome of the grass carp (Ctenopharyngodon idellus) provides insights into its evolution and vegetarian adaptation
Authors: Yaping Wang, Ying Lu, Yong Zhang, Zemin Ning, Yan Li, Qiang Zhao, Hengyun Lu, Rong Huang, Xiaoqin Xia, Qi Feng, Xufang Liang, Kunyan Liu, Lei Zhang, Tingting Lu, Tao Huang, Danlin Fan, Qijun Weng, Chuanrang Zhu, Yiqi Lu, Wenjun Li, Ziruo Wen, Congcong Zhou, Qilin Tian, Xiaojun Kang, Mijuan Shi, Wanting Zhang, Songhun Jang, Fukuan Du, Shan He, Lanjie Liao, Yongming Li, Bin Gui, Huihui He, Zhen Ning, Cheng Yang, Libo He, Lifei Luo, Rui Yang, Qiong Luo, Xiaochun Liu, Shuisheng Li, Wen Huang, Ling Xiao, Haoran Lin, Bin Han, Zuoyan Zhu
Journal: Nature Genetics (2015)

Bin Han and colleagues report the draft genome sequence of the grass carp Ctenopharyngodon idellus, a major commercially farmed species of freshwater fish. Analyses of the grass carp genome identify lineage-specific duplications that may have contributed to the adaptation of this species to a vegetarian diet. The grass carp is an important farmed fish, accounting for ∼16% of global freshwater aquaculture, and has a vegetarian diet. Here we report a 0.9-Gb draft genome of a gynogenetic female adult and a 1.07-Gb genome of a wild male adult. Genome annotation identified 27,263 protein-coding gene models in the female genome. A total of 114 scaffolds consisting of 573 Mb are anchored on 24 linkage groups. Divergence between grass carp and zebrafish is estimated to have occurred 49–54 million years ago. We identify a chromosome fusion in grass carp relative to zebrafish and report frequent crossovers between the grass carp X and Y chromosomes. We find that transcriptional activation of the mevalonate pathway and steroid biosynthesis in liver is associated with the grass carp's adaptation from a carnivorous to an herbivorous diet. We believe that the grass carp genome could serve as an initial platform for breeding better-quality fish using a genomic approach.
In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000–2001
Authors: M.E. Jones, R.S. Blosser-Middleton, I.A. Critchley, J.A. Karlowsky, C. Thornsberry, D.F. Sahm
Journal: Clinical Microbiology and Infection (2003)
Albumin-bound paclitaxel (nab-P) may play an important role in the treatment of non-small-cell lung cancer (NSCLC) patients
Authors: Alexandros Kavvadias, Andriani Charpidou, Ioannis Gkiozos, Georgios Tsoukalas, Konstantinos N. Syrigos
Journal: European Respiratory Journal (2011)

Background: Taxanes have significantly contributed in the treatment of NSCLC. They are hydrophobic substances, they need premedication and long infusion time.

Aim and objectives: Nab-P is a novel water-soluble formulation of paclitaxel (P) that uses serum albumin as a vehicle into a nanoparticle suspension. We present the latest data on the use of nab-P in the treatment of NSCLC.

Method: Our source was MEDLINE database till the end of 2010 with key words nab-P, NSCLC.

Results: We found three phase I, three phase II trials and one dose-finding non-randomized trial for a phase III trial and the results of a phase III randomized trial presented in the ASCO meeting 2010. The technical advantages over P including shorter infusion time of 30 minutes and no need of premedication. Nab-P has significant single agent activity. When combined with carboplatin (C) or C and bevacizumab, has promising activity in the first line treatment of NSCLC. In the phase III trial with 1038 patients, nab-P combined with C significantly improves response rate (ORR) versus PC. Squamous cell carcinoma patients treated with nab-PC significantly improved ORR versus PC. Toxicity profile presented less high-grade adverse events and minimal risk of hypersensitivity reactions.

Conclusion: Latest data for nab-P suggests a safe and efficient profile. Nab-P may replace the older taxanes in case of hypersensitivity reactions. Patients with squamous histotype may have an advantage if treated with nab-P but further investigation is needed.
Abstract IA21: The basis of immune suppression in murine pancreatic ductal adenocarcinoma
Authors: Douglas T. Fearon
Journal: Cancer Research (2015)

Abstract Immune therapy of human pancreatic ductal adenocarcinoma (PDAC) with the T cell checkpoint antagonists, anti-CTLA-4 and anti-PD-L1, has been unsuccessful. To determine the reason for this, we studied the KPC mouse model of autochthonous PDAC in which cancer cells express KrasG12D and p53R172H, and have lost the wild type p53 allele (LOH). These tumors resemble human PDAC in not responding to treatment with anti-CTLA-4 or anti-PD-L1. PDAC-bearing mice have CD8+ T cells specific for antigen(s) expressed by cancer cells. Thus, the ineffectiveness of T cell checkpoint antagonist immune therapy is not explained by the absence of an anti-tumor immune response, and immune suppression in the tumor microenvironment must occur mainly by another means. We have shown that this immune suppressive process depends on the stromal cell known as the “cancer-associated fibroblast” (CAF) that is identified by the membrane protein marker, “fibroblast activation protein” (FAP). Conditionally depleting the FAP+ CAF (Kraman M, et al., Science 2010) leads to T cell-mediated slowing of PDAC growth, and co-treatment with anti-PD-L1 enhances this effect (Feig C, et al. PNAS 2013). Three observations directed attention to the chemokine, CXCL12, as the mediator of immune suppression: the FAP+ CAF is the source of CXCL12 mRNA in PDACs; CXCL12 protein selectively “coats” the cancer cells; and T cells are excluded from the CXCL12-coated cancer cell-containing regions of the tumor. We treated PDAC-bearing mice for 24 hr with AMD3100/Plerixafor, a small molecule antagonist of the CXCL12 receptor, CXCR4, alone or together with anti-PD-L1. Tumors from AMD3100-treated mice exhibit frequent T cells within cancer cell-containing regions, and tumors from dual treated mice have even more T cells. Importantly, whereas tumor volume doubles in control mice in 6 days, AMD3100 alone arrests tumor growth, and AMD3100 + anti-PD-L1 treatment decreases tumor volume by 15%. Both therapies eliminate almost all cancer cells, leaving a residual mass containing only PanIN, inflammatory cells, and desmoplastic matrix. These findings may be relevant not only to human PDAC, but also to colorectal and ovarian carcinoma, all of which also contain FAP+ CAFs and CXCL12-coated cancer cells, demonstrate exclusion of T cells from the vicinity of cancer cells, and are resistant to therapy with anti-PD-1/anti-PD-L1. Citation Format: Douglas T. Fearon. The basis of immune suppression in murine pancreatic ductal adenocarcinoma. [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer: Innovations in Research and Treatment; May 18-21, 2014; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2015;75(13 Suppl):Abstract nr IA21.
Abstract 9516: Chronic and Continuous Use of Adaptive Servo-Ventilation Improves and Keeps Cardiac Function in Patient With Heart Failure With Central Sleep Apnea
Authors: Tatsunori Ikeda, Manabu Fujimoto, Kazuyasu Okeie, Masakazu Yamamoto, Hisayoshi Murai, Soichirou Usui, Masayuki Takamura, Shuichi Kaneko
Journal: Circulation (2014)

Central sleep apnea (CSA) is closely associated with poor prognosis in heart failure (HF) patient. Adaptive servo-ventilation (ASV) is a new treatment for HF with CSA patient. However, there is little evidence in chronic use. We examined 70 HF with CSA patients treated with ASV seen between May 2008 and November 2012 in our hospital, retrospectively, who had not been admitted to the hospital due to worsening HF in the 6 months before initiating ASV therapy. We divided it into 2 groups: (A) non-continues-ASV-treated patients; (B) continues-ASV-treated patients. 18 patients (group A) used ASV only in the hospital and could not continue because of its discomfort. 52 patients (group B) could continue to night time use the ASV device after leaving the hospital. The median follow up time was 364 days after leaving hospital. There were almost no significant differences in the baseline characteristics between two groups. In group B, during 6, 12, 24 months observation, left ventricular ejection fraction (45.5 +/-...
ABC of labour care: Preterm labour and premature rupture of membranes
Authors: P. Steer, C. Flint
Journal: BMJ (1999)

The length of human pregnancy is variable, reflecting the advantages to the fetus, which would benefit by staying in the uterus to grow more, and to the mother, for whom earlier delivery might reduce pelvic damage (see the second article in the series). The result of this interaction is a relatively high incidence of premature deliveries. In the United Kingdom the incidence of preterm delivery (before 37 weeks) is about 7%, and in many developing countries, it is much higher. The baby is delivered before its homoeostatic mechanisms are properly developed and so is prone principally to the respiratory distress syndrome, hypothermia, hypoglycaemia, and jaundice.



Distribution of 24 675 deliveries by gestational age (determined by early ultrasound scanning dates) for a British maternity hospital (Queen's Medical Centre, Nottingham), 1988-95



Socioeconomic factors influence the incidence of preterm labour. Preterm birth is significantly more common in young women, those with low body weight (body mass index <19), those of lower social class, unmarried or unsupported mothers, and smokers. Some medical factors may increase the risk of preterm birth—for example, previous preterm delivery, persistent vaginal bleeding in early pregnancy, and heart disease. Cervical incompetence is a rare cause of preterm labour, sometimes preventable by cervical cerclage (a purse string suture around the cervix as close to the internal os as possible). The Medical Research Council's trial showed a small but significant benefit from this procedure, even in women with equivocal risk factors.

### Major risks of early preterm delivery

### Risk factors for preterm labour

### Major causes of preterm labour

Infection, usually …
Failure of Immunization Against Tumorigenesis&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Richmond T. Prehn
Journal: JNCI Journal of the National Cancer Institute (1961)

Journal Article Failure of Immunization Against Tumorigenesis Get access Richmond T. Prehn, M.D. Richmond T. Prehn, M.D. Department of Pathology, University of Washington, Seattle, Washington Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 26, Issue 1, January 1961, Pages 223–227, https://doi.org/10.1093/jnci/26.1.223 Published: 01 January 1961 Article history Received: 03 August 1960 Published: 01 January 1961
P B S-1086, a “Pan-Rel” Inhibitor, Decreases Viability of Chronic Lymphocytic Leukemia Cells
Authors: Susan J Tudhope, Evan A Mulligan, Jill E Hunter, Geoffrey P Summerfield, Scott Marshall, Jonathan Wallis, Helen Marr, Paul Evans, Chris Lowe, Barbara W Durkacz, Jie Zhang, Jeffrey Meshulam, Kathryn Bobb, Elaine Willmore
Journal: Blood (2012)
Abstract 18710: The Systolic to Diastolic Duration Ratio in Children With Dilated Cardiomyopathy Who Need Heart Transplantation or Die
Authors: Tapas Mondal, Paul Kantor, Luc Mertens, Mark K Friedberg
Journal: Circulation (2010)

Introduction: The systolic: diastolic duration ratio (S:D ratio) is an indicator of global cardiac performance independent of heart rate that may be useful for prognosis. We have previously shown t...
576. Antitumoral Effect Mediated by Two SFV-IL-12 Expression Vectors in a Murine Model of Colon Adenocarcinoma
Authors: Juan R. Rodriguez-Madoz, Erkuden Casales, Min Guan, Jesus Prieto, Cristian Smerdou
Journal: Molecular Therapy (2004)

Two Semliki Forest Virus (SFV) based vectors expressing murine interleukin-12 (IL-12) have been developed and their antitumoral efficacy has been tested in the MC38 mouse model of colon carcinoma. In SFV-IL-12 vector, genes coding for IL-12 subunits were cloned under a single viral subgenomic promoter using an IRES between them. SFV-enhIL-12 vector carries each gene fused to the SFV capsid translation enhancer, under independent viral subgenomic promoters. Recombinant SFV viral particles were produced and IL-12 expression was tested in supernatants of BHK and MC38 infected cells by ELISA. Biologically active IL-12 was expressed at high levels from both vectors with a 9-fold increase in the case of SFV-enhIL-12. Single tumor nodules were implanted in the flank of C57BL/6 mice by subcutaneous injection of MC38 colon carcinoma cells and treated with a single intratumoral injection of SFV-IL-12, SFV-enhIL-12, and SFV-LacZ or saline as controls. With 108 viral particles of SFV-IL-12 or SFV-enhIL-12 more than 80% of treated mice experienced complete tumor regression with long-term tumor-free survival. However, when lower doses of vectors were used SFV-enhIL-12 was more efficient than SFV-IL-12 in inducing antitumoral responses. In order to compare the SFV vectors with other viral vectors more commonly used in gene therapy some groups of mice were treated in parallel with a first generation adenovirus vector coding IL-12 (Ad-IL-12). Both SFV vectors were more efficient inducing antitumoral responses than Ad-IL-12. Treatment with repeated intratumoral injection of suboptimal doses of SFV-enhIL-12 increased significatively the antitumoral response. This effect was also observed with Ad-IL-12 but only when 108 PFU were injected. In addition, all mice that rejected tumors showed specific protection against tumor rechallenge. CTL assays and depletion studies showed a CD8+ T cell dependent response. Intratumoral expression was measured in tumor homogenates after infection with SFV IL-12 vectors resulting in a maximum cytokine level at 24 hours postinjection. The length of expression was also determined in vivo by intratumoral injection of a SFV vector expressing luciferase (SFV-Luc) using the Xenogen IVIS system. Luciferase expression localized into the tumor mass for at least 6 days after infection. Systemic administration of SFV-Luc in tumor bearing mice by intraperitoneal or intravenous injection produced high luciferase expression in large body areas but it did not localized at the tumor nodule.
Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration
Authors: Jeffrey S. Heier, Andrew N. Antoszyk, Peter Reed Pavan, Steven R. Leff, Philip J. Rosenfeld, Thomas A. Ciulla, Richard F. Dreyer, Ronald C. Gentile, Judy P. Sy, Gary Hantsbarger, Naveed Shams
Journal: Ophthalmology (2006)
Vaccine Rumors, Funding Shortfall Threaten to Derail Global Polio Eradication Efforts
Authors: Mike Mitka
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Roentgenographical Aspects of the Differential Diagnosis of Disease of the Gall Bladder
Authors: B. H. Nichols
Journal: Annals of Internal Medicine (1927)

Article1 August 1927Roentgenographical Aspects of the Differential Diagnosis of Disease of the Gall BladderB. H. NICHOLS, M.D.B. H. NICHOLS, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-1-2-92 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThere is no more fertile field for the roentgenological study of pathological conditions than that presented by the upper right abdominal quadrant. It is the uncertainty which attends the diagnosis of lesions within this area that has for so long demanded the exploratory operation. This is well illustrated by the finding in a recent survey of the cases of hydronephrosis of the right kidney seen at the Cleveland Clinic that in thirty per cent of these cases an exploratory operation had previously been performed for a supposed gall-bladder lesion or other abdominal disorder. The time has now arrived, however, when... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Cleveland Clinic Cleveland, Ohio*Presented at the Cleveland Clinical Week of the American College of Physicians, February 23, 1927. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 August 1927Volume 1, Issue 2Page: 92-95KeywordsBladderKidneysLesions ePublished: 1 December 2008 Issue Published: 1 August 1927 PDF downloadLoading ...
Products with low IgA content may be used in patients with total IgA deficiency
Authors: S. Misbah
Journal: BMJ (1996)

Case 1-A 76 year old woman received the treatment for multifocal motor neuropathy.One week after treatment she developed a widespread erythematous, exfoliating rash, which was diagnosed after skin biopsy as being severe erythroderma.This required three months of intensive and predominantly inpatient dermatological care.The neuropathy initially responded to the intravenous immunoglobulin but then relapsed.After extensive patch testing with various brands of intravenous immunoglobulin, none of which resulted in a positive reaction, she was given a further course covered by oral steroids, but within six hours of the first dose the rash returned.Case 2-A 66 year old man with inclusion body myositis developed itchy skin eruptions six days after receiving the Scottish preparation of intravenous immunoglobulin.Skin biopsy suggested an allergic aetiology.He had a further six courses of the same preparation at monthly intervals with oral steroid cover.No further complications developed.Case 3-A 48 year old man with multifocal motor neuropathy developed a widespread eczematous rash 10 days after treatment with intravenous immunoglobulin.He was admitted to hospital after failure of outpatient treatment.Skin biopsy showed perivascular inflammation, hyperkeratosis, and parakeratosis without evidence of vasculitis.Case 4-A 55 year old man received intravenous immunoglobulin for multifocal motor neuropathy.One week after treatment he developed widespread itchy, scaly eruptions, mainly on the arms and legs, which persisted for four weeks.Recovery was spontaneous and uneventful.Serious side effects of intravenous immuno- globulin are rare.There are only a few reports of skin reactions in the literature2; although rarely life threatening, they may cause considerable distress (as they did in cases 1 and 3).A patient has been successfully treated with intravenous immuno- globulin and steroid cover after developing eczema,3 and the combination of intravenous immunoglobulin and steroid has been evaluated recently.4This may well be optimal treatment, if only because the side effects of the immunoglobu- lin are lessened, but our experience is that the skin condition may recur despite such treatment.
A Hormone-Free Male "Pill"?
Authors: Joan Stephenson
Journal: JAMA (2003)

A drug recently approved in Europe to treat the genetic disorder Gaucher disease might someday find its way into the bedroom as a hormone-free male contraceptive, suggest animal studies led by researchers at the University of Oxford, in England (Proc Natl Acad Sci U S A. 2002;99:17173-17178).